MA44672A - Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate - Google Patents

Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate

Info

Publication number
MA44672A
MA44672A MA044672A MA44672A MA44672A MA 44672 A MA44672 A MA 44672A MA 044672 A MA044672 A MA 044672A MA 44672 A MA44672 A MA 44672A MA 44672 A MA44672 A MA 44672A
Authority
MA
Morocco
Prior art keywords
hydroxybutanedioate
dimethoxyquinolin
fluoropheny
dicarboxamide
cyclopropane
Prior art date
Application number
MA044672A
Other languages
English (en)
Inventor
Dana T Aftab
Alan Arroyo
Mark Dean
Colin Hessel
Steven Lacy
Dale Miles
Christian Scheffold
Gisela Schwab
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA44672A publication Critical patent/MA44672A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA044672A 2016-04-15 2017-04-17 Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate MA44672A (fr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201662323536P 2016-04-15 2016-04-15
US201662323556P 2016-04-15 2016-04-15
US201662323548P 2016-04-15 2016-04-15
US201662324157P 2016-04-18 2016-04-18
US201662324158P 2016-04-18 2016-04-18
US201662324176P 2016-04-18 2016-04-18
US201662338195P 2016-05-18 2016-05-18
US201662338154P 2016-05-18 2016-05-18
US201662338240P 2016-05-18 2016-05-18
US201662338267P 2016-05-18 2016-05-18
US201662345652P 2016-06-03 2016-06-03
US201762457471P 2017-02-10 2017-02-10
US201762457613P 2017-02-10 2017-02-10
US201762457671P 2017-02-10 2017-02-10

Publications (1)

Publication Number Publication Date
MA44672A true MA44672A (fr) 2019-02-20

Family

ID=60042048

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044672A MA44672A (fr) 2016-04-15 2017-04-17 Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate

Country Status (7)

Country Link
US (3) US11141413B2 (fr)
EP (1) EP3442531A1 (fr)
CN (1) CN109069499A (fr)
CA (1) CA3020749A1 (fr)
MA (1) MA44672A (fr)
RU (1) RU2748549C2 (fr)
WO (1) WO2017181187A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029506B1 (ru) * 2011-05-02 2018-04-30 Экселиксис, Инк. Способ лечения рака и раковой боли в костях
EP3442531A1 (fr) 2016-04-15 2019-02-20 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
IL268138B (en) * 2017-01-20 2022-08-01 Exelixis Inc Combinations of cabozantinib and atezolizumab for the treatment of cancer
CN117603138A (zh) 2018-01-26 2024-02-27 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
WO2020101596A2 (fr) * 2018-08-10 2020-05-22 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Composition de capsule comprenant du sunitinib
AU2021206613A1 (en) * 2020-01-06 2022-07-21 Aravive Inc. Methods of treating clear cell renal carcinoma (ccRCC) using AXL decoy receptors
CA3162074A1 (fr) * 2020-01-10 2021-07-15 Joseph HORVATINOVICH Methodes de traitement de tumeurs
AU2021297151A1 (en) * 2020-06-17 2023-02-09 Eisai R&D Management Co., Ltd. Methods for treating cancer or von-Hippel Lindau disease using a combination of a PD-1 antagonist, a HIF-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
CA2572331A1 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
CA2603748A1 (fr) 2005-04-06 2006-10-12 Exelixis, Inc. Modulateurs c-met modulators et procedes d'utilisation
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
MX2011005038A (es) 2008-11-13 2011-06-16 Exelisis Inc Metodo de preparacion de derivados de quinolina.
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス， インコーポレイテッド キノリン誘導体の調製方法
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
NZ597695A (en) 2009-07-17 2014-05-30 Exelixis Inc Crystalline forms of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl} oxy)phenyl]-n’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
CN103221035A (zh) 2010-07-16 2013-07-24 埃克塞里艾克西斯公司 C-met调节剂药物组合物
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
EP2621481B2 (fr) 2010-09-27 2022-10-19 Exelixis, Inc. Inhibiteurs de met et vegf à double effet pour le traitement du cancer de la prostate résistant à la castration et des métastases osseuses ostéoblastiques
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
KR20190049907A (ko) 2011-02-10 2019-05-09 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EA029506B1 (ru) 2011-05-02 2018-04-30 Экселиксис, Инк. Способ лечения рака и раковой боли в костях
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EA201490676A1 (ru) 2011-09-22 2015-02-27 Экселиксис, Инк. Способ лечения остеопороза
JP2014532184A (ja) * 2011-10-12 2014-12-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 多重化キナーゼ阻害剤ビーズ及びその使用
TWI619694B (zh) 2011-10-20 2018-04-01 艾克塞里克斯公司 用於製備喹啉衍生物之方法
TW201818937A (zh) 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
EP2844254A1 (fr) 2012-05-02 2015-03-11 Exelixis, Inc. Double modulateur met-vegf pour traiter des métastases osseuses ostéolytiques
US20150238477A1 (en) 2012-09-07 2015-08-27 Exelixis, Inc. Method of Treating Lung Adenocarcinoma
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
CN105121412B (zh) 2013-03-15 2019-07-12 埃克塞里艾克西斯公司 N-(4-{[6，7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的代谢物
EP2981263B1 (fr) 2013-04-04 2022-06-29 Exelixis, Inc. Formulation de dosage du cabozantinib et utilisation dans le traitement du cancer
JP2016515628A (ja) 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
EP3906921A1 (fr) 2014-04-25 2021-11-10 Exelixis, Inc. Procédé de traitement de l'adénocarcinome pulmonaire
US11124481B2 (en) 2014-07-31 2021-09-21 Exelixis, Inc. Method of preparing fluorine-18 labeled Cabozantinib and its analogs
CA2957466C (fr) 2014-08-05 2023-10-17 Exelixis, Inc. Combinaison de medicaments pour traiter le myelome multiple
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma
EP3442531A1 (fr) 2016-04-15 2019-02-20 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
IL268138B (en) 2017-01-20 2022-08-01 Exelixis Inc Combinations of cabozantinib and atezolizumab for the treatment of cancer

Also Published As

Publication number Publication date
CA3020749A1 (fr) 2017-10-19
RU2018140055A3 (fr) 2020-08-05
US20230045783A9 (en) 2023-02-09
CN109069499A (zh) 2018-12-21
US20220401433A1 (en) 2022-12-22
US11141413B2 (en) 2021-10-12
RU2018140055A (ru) 2020-05-15
US20190209547A1 (en) 2019-07-11
US20220000857A1 (en) 2022-01-06
WO2017181187A1 (fr) 2017-10-19
RU2748549C2 (ru) 2021-05-26
EP3442531A1 (fr) 2019-02-20

Similar Documents

Publication Publication Date Title
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
FR21C1039I2 (fr) Composés destinés à traiter l'amyotrophie spinale
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
DK3340981T3 (da) Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser
DK3606909T3 (da) Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid
IL255919A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror gamma and the treatment of disease
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
EA201790317A1 (ru) Ингибиторы smyd
EA201790271A1 (ru) Ингибиторы гликозидазы
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
FR3023954B1 (fr) Methode pour inverser l'activite d'une faille et la contrainte tectonique
BR112016018450A2 (pt) formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
IL256805B (en) Compounds -4-)-n aryl(phenyl)-2-(4-(1,1-(difluoroalkyl(phenyl)-acetamide and their use for the treatment of diseases modulated by rorgt
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
FI20145492A (fi) Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
DK3240538T3 (da) Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
MA46355A (fr) Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide
DK3424924T3 (da) Ureaforbindelse, fremgangsmåde til fremstilling deraf og medicinsk anvendelse deraf
DK3429998T3 (da) Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
MA43274A (fr) Gilet portable pour l'application de thérapie pulmonaire et procédé associé
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
DK3526207T3 (da) Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter